Skip to main content

Advertisement

Table 5 Number (%) of participants with dermatological endpoints and treatment differences

From: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Adverse event category Number (%) Treatment difference (95% CI)
12 mg (N = 652) 40 mg (N = 652) Placebo (N = 653) 12 mg vs. placebo 40 mg vs. placebo
Hypopigmentation composite endpointa 16 (2.5) 16 (2.5) 14 (2.1) 0.31 (− 1.39, 2.04) 0.31 (− 1.39, 2.04)
Hypopigmentation event of clinical interest 10 (1.5) 9 (1.4) 11 (1.7) − 0.15 (− 1.64, 1.32) − 0.3 (− 1.77, 1.12)
Rash event of clinical interest 30 (4.6) 28 (4.3) 8 (1.2) 3.38 (1.63, 5.39) 3.07 (1.36, 5.04)
Severe rashb 0 (0.0) 0 (0.0) 0 (0.0) 0 0
  1. aComprised of the following terms: skin hypopigmentation, skin depigmentation, vitiligo, leukoderma, hypopigmentation of the eyelid, and idiopathic guttate hypomelanosis
  2. bStevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms